POLYBUTYRATE

Serial Number 87235350
602

Registration Progress

Application Filed
Nov 14, 2016
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

POLYBUTYRATE

Basic Information

Serial Number
87235350
Filing Date
November 14, 2016
Abandonment Date
July 5, 2018
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Aug 13, 2018
Classes
005

Rights Holder

Tesseract Medical Research, LLC

16
Address
1370 Trancas Street, Suite 350
Napa, CA 94558

Ownership History

Tesseract Medical Research, LLC

Original Applicant
16
Napa, CA

Legal Representation

Attorney
Kim R. Pearson

USPTO Deadlines

All Deadlines Cleared

All 6 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

35 events
Date Code Type Description Documents
Aug 13, 2018 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Aug 13, 2018 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Jan 5, 2018 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jan 5, 2018 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jan 5, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 28, 2017 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Aug 1, 2017 PBCR Z WITHDRAWN FROM PUB - OG REVIEW QUERY Loading...
Jul 20, 2017 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Jul 19, 2017 ALIE A ASSIGNED TO LIE Loading...
Jul 19, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 19, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 19, 2017 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 19, 2017 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jul 19, 2017 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 19, 2017 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 19, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 23, 2017 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
May 15, 2017 CNFR R FINAL REFUSAL WRITTEN Loading...
May 15, 2017 GNFR O FINAL REFUSAL E-MAILED Loading...
May 15, 2017 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Apr 29, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 28, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 28, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 11, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 11, 2017 GNRT O NON-FINAL ACTION E-MAILED Loading...
Apr 11, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 31, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 30, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 30, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 21, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 21, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 21, 2017 GNRT F NON-FINAL ACTION E-MAILED Loading...
Feb 21, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 18, 2016 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 17, 2016 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Dietary supplements; nutritional supplements; medical foods, namely, medical food supplements and dietetic food supplements, both containing short-chain fatty acids in single molecule form with a release agent that enhances solubility and absorption; nutritional ingredients, namely, a blend of nutrients, namely, short-chain fatty acids in single molecule form with a release agent that ensures solubility and absorption, that are an integral component of medicals foods, for short-chain fatty acid deficiencies in individuals with Autism Spectrum Disorder; nutraceuticals for use as dietary supplements and nutritional supplements; vitamin preparations and mineral preparations to mitigate short-chain fatty acid microbiome deficiencies in individuals with Autism Spectrum Disorder; dietary supplements for restoring health in individuals with diseases, disorders, nutritional deficiencies, and adverse health conditions; therapeutic agents for human medical, medicinal, and therapeutic purposes, namely, increasing butyric acid in the gastrointestinal tract; functional nutrients containing butyric acid and acetic acid to mitigate short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder; pharmaceutical preparations to mitigate short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder; specialty nutraceuticals for the dietary management of diseases, disorders, and nutritional deficiencies, namely, short-chain fatty acid gut microbiome deficiencies in individuals with Autism Spectrum Disorder and deficiencies of butyrate in the gastrointestinal tract
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005